Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA accepts Merck & Co.'s Keytruda filing for first-line treatment of NSCLC, grants priority review
FDA accepts Merck & Co.'s Keytruda filing for first-line treatment of NSCLC, grants priority review
FDA accepts Merck & Co.'s Keytruda filing for first-line treatment of NSCLC, grants priority review
Submitted by
admin
on September 7, 2016 - 10:13am
Source:
First Word Pharma
News Tags:
Merck
FDA
Keytruda
non-small cell lung cancer
priority review
Headline:
FDA accepts Merck & Co.'s Keytruda filing for first-line treatment of NSCLC, grants priority review
Do Not Allow Advertisers to Use My Personal information
